Don't Forget - the Deadline for Adopting an Expanded Access Policy Under the 21st Century Cures Act is Looming

January 27, 2017 Alerts and Newsletters

As many of you are aware, the 21st Century Cures Act (Pub. L. 114-255) ("Cures Act") was signed into law by President Barack Obama on December 13, 2016.

Under Section 3032 of the Cures Act ("Section 3032"), pharmaceutical companies are generally required to have publicly available policies explaining how the company evaluates and responds to patient requests for certain experimental drugs outside of clinical trials. The deadline for adopting these policies with respect to a particular investigational drug is the later of February 12, 2017 or the first initiation of a phase 2 or 3 study of the investigational drug. For those of you who have investigational drugs that are already in phase 2 or 3, the February 12, 2017 deadline is approaching fast.

Section 3032 requires manufacturers or distributors of investigational drugs for diagnosing, monitoring, or treating serious diseases or conditions to develop and make publicly available (e.g., on the company's website) the manufacturer's policy for responding to requests for so-called "expanded access" use of the drugs. The policy must include the following information:

  • contact information for the manufacturer or distributor for expanded access requests, in order to facilitate communication regarding such requests;
  • procedures for making expanded access requests;
  • the manufacturer's or distributor's general criteria for reviewing and responding to expanded access requests for individual patients;
  • the anticipated length of time for the manufacturer or distributor to acknowledge receipt of expanded access requests; and
  • a link or reference to the clinical trial record included in the clinical trial registry data bank maintained by the National Institutes of Health pursuant to section 402(j) of the Public Health Service Act, which includes a field specifying whether or not there is expanded access to an investigational drug and, if so, how to obtain information about such access.

While manufactures and distributors of investigational drugs must make their expanded access policy publically available, nothing in Section 3032 (or in the Cures Act more broadly) requires these manufacturers and distributors to grant an individual patient's request for expanded access to an investigational drug. Accordingly, an individual patient's expanded access request can be denied for any reason, provided such denial is consistent with the published policy. Additionally, under Section 3032, manufacturers and distributors of investigational drugs are entitled to revise their expanded access policies at any time.

For more information regarding Section 3032, or for assistance drafting your expanded access policy, please contact Andrew Rusczek.

This communication is intended for general information purposes and as a service to clients and friends of Verrill Dana, LLP. This publication, which may be considered advertising under the ethical rules of certain jurisdictions, should not be construed as legal advice or a legal opinion on any specific facts or circumstances, nor does it create attorney-client privilege.

Firm Highlights


Multi-Site Global Research

Developed and negotiated site and coordinating center agreements in connection with a multi-site, international, National Institutes of Health (NIH)-funded study, and advised on regulatory issues related to the conduct of the study and subsequent...


Conflicts of Interest

Reviewed medical center's systems, policies and procedures for identifying, assessing, and managing investigator and institutional conflicts of interest.


Michael K. Fee to Lead Verrill’s Nationally-Recognized Health Care and Life Sciences Practice Amidst Recent Changes

(August 31, 2020) – Verrill is pleased to announce Michael K. Fee as the new leader of Verrill’s nationally-recognized Health Care & Life Sciences Group. The Group has a long history of representing a...


Nearly 80 Verrill Attorneys Recognized by Best Lawyers® 2021, Including a Dozen Named Lawyers of the Year

(August 24, 2020) – Nearly 80 Verrill attorneys were recognized as "Best Lawyers" by Best Lawyers® 2021 , including 12 attorneys named “Lawyer of the Year,” a distinguished recognition for only a single lawyer...


FDA Issues Guidance on IRB Review of Non-Emergency Individual Patient Expanded Access Requests for Investigational Drugs and Biological Products to Treat COVID-19

Prompted by a substantial increase in requests for individual patient access to investigational drugs and biologics to treat COVID-19, the U.S. Food & Drug Administration (“FDA”) issued guidance on June 2, 2020 that outlines...


FDA Updates its Guidance on Conducting Clinical Trials During COVID-19 Public Health Emergency

On April 16, 2020, the U.S. Food & Drug Administration (“FDA”) again updated its guidance on the “Conduct of Clinical Trials of Medical Products during COVID-19 Public Health Emergency,” adding seven new questions and...


EU-U.S. Privacy Shield Invalidated: Does Your Company Have a Plan B?

On Thursday, July 16, 2020, the Court of Justice of the European Union (“CJEU”) invalidated the EU-U.S. Privacy Shield (“Privacy Shield”) in Data Protection Commissioner v. Facebook Ireland and Maximillian Schrems (Case C-311/18...


38 Verrill Attorneys, Across Four Offices, Recognized in 2020 Chambers & Partners Guide

(April 27, 2020) – Verrill has been rated as a Leading Firm in a total of ten categories and subcategories as evaluated by London-based Chambers & Partners , one of the world's most respected...


European Union GDPR—Institution

Counseled a preeminent health system and academic medical center on its compliance with the European Union General Data Protection Regulation (GDPR) in relation to its clinical and research activities, including its international research studies...


News Flash: HHS Issues Statement Removing Premarket Review Requirements for Laboratory Developed Tests (“LDTs”), Including COVID-19 LDTs

What happened? On August 19, 2020, the U.S. Department of Health and Human Services (“HHS”) issued a single paragraph statement rescinding U.S. Food and Drug Administration (“FDA”) guidance documents concerning premarket review of Laboratory...